Basel Medical Complies with Nasdaq Periodic Filing Requirements
Basel Medical received notification from Nasdaq that based on the company's amended annual report on Form 20-F for FY25, filed with the SEC on March 13, Nasdaq has now determined that the company has complied with the periodic filing requirement for Nasdaq. Accordingly, the prior deficiency relating to the Periodic Filing Rule has now been resolved.
Trade with 70% Backtested Accuracy
Analyst Views on BMGL
About BMGL
About the author
Basel Medical Regains Nasdaq Compliance After Filing
- Compliance Restoration: Basel Medical has regained compliance with Nasdaq listing requirements after submitting its amended annual report, effectively resolving a prior filing deficiency and demonstrating proactive management in compliance matters.
- Financial Reporting Issues: The Singapore-based healthcare provider received a delinquency notice from Nasdaq in December 2025 due to the initial incompleteness of its FY2025 Form 20-F, highlighting challenges in the company's financial transparency.
- Stock Price Reaction: Following the compliance restoration announcement, Basel Medical's stock price traded 2.7% higher during pre-market hours on Tuesday, indicating a positive market response to the news and potentially boosting investor confidence.
- Future Outlook: With the resolution of compliance issues, Basel Medical is positioned to attract more investor interest in the future, enhancing its market position and competitiveness within the healthcare sector.
Basel Medical Group (BMGL) Receives Nasdaq Notice, Must Regain Compliance in 180 Days
- Nasdaq Warning: Basel Medical Group has received a notice from Nasdaq for failing to meet the $1 minimum bid price requirement after 30 consecutive trading days below this level, facing potential delisting risks and needing to take action within 180 days.
- Compliance Deadline: The company must maintain a closing bid price of at least $1 for 10 consecutive business days within 180 days, with a potential reverse stock split required before July 21, 2026, to meet Nasdaq's requirements.
- Response Plan: Basel Medical Group stated it is working with advisers to prepare a plan to address the listing non-compliance, aiming to implement effective measures to restore its stock price and ensure continued listing.
- Stock Price Reaction: Despite facing compliance challenges, Basel Medical Group's shares rose by 2.54%, indicating market confidence in the company's ability to regain compliance in the future.
Basel Medical Group Receives Delinquency Notice from Nasdaq
Delinquency Notification: Basel Medical Group Ltd. received a delinquency notification from Nasdaq due to an incomplete annual report for the fiscal year ending June 30, 2025, which lacked an auditor's opinion on its financial statements.
Compliance Timeline: The company has 60 days to submit a plan to regain compliance with Nasdaq rules, with a potential extension of up to 180 days if the plan is approved.
Financial Performance: For the fiscal year 2025, Basel Medical reported a net loss of S$12.09 million, a significant decline from a profit of S$2.07 million the previous year, despite an increase in sales from S$10.05 million to S$11.32 million.
Stock Performance: On the Nasdaq, BMGL shares closed at $1.14, reflecting a 2.52% decrease.
Basel Medical Group Faces Compliance Risk for Late 20-F Filing with Nasdaq
- Compliance Risk: Basel Medical Group has been notified by Nasdaq for failing to submit its 20-F annual report with an auditor's opinion, facing compliance risks that require a rectification plan within 60 days to avoid further penalties.
- Rectification Timeline: If the plan is accepted, Nasdaq may grant an exception of up to 180 days until May 18, 2026, to regain compliance, impacting the timeliness of future financial reports.
- Financial Audit Issues: The delay stems from the auditor NLA DFK Assurance PAC's failure to provide the necessary audit opinion, highlighting potential weaknesses in the company's financial transparency and compliance, which could affect investor confidence.
- Market Impact: Although trading on Nasdaq is currently unaffected, ongoing compliance issues may negatively impact the company's stock price and market reputation, necessitating stronger internal controls to prevent similar occurrences in the future.
Basel Medical Group Putting On Hold On The Acquisition of BTC Digital Asset
Acquisition on Hold: Basel Medical Group Ltd has decided to pause its acquisition of Bitcoin (BTC) digital assets due to ongoing regulatory reviews by US authorities, seeking greater clarity before proceeding with the transaction.
Company Overview: Basel Medical Group is a Singapore-based provider specializing in orthopedic and trauma services, with over 20 years of experience and a strong business model supported by relationships in various industries.
Basel Medical Group Puts the acquisition of BTC digital asset on hold
Acquisition on Hold: Basel Medical Group has decided to pause its acquisition of BTC digital assets, following a mutual agreement with Bitcoin holders.
Market Response: Following the announcement, BMGL shares experienced a 5% increase in post-market trading on Thursday.
Basel Medical Regains Nasdaq Compliance After Filing
- Compliance Restoration: Basel Medical has regained compliance with Nasdaq listing requirements after submitting its amended annual report, effectively resolving a prior filing deficiency and demonstrating proactive management in compliance matters.
- Financial Reporting Issues: The Singapore-based healthcare provider received a delinquency notice from Nasdaq in December 2025 due to the initial incompleteness of its FY2025 Form 20-F, highlighting challenges in the company's financial transparency.
- Stock Price Reaction: Following the compliance restoration announcement, Basel Medical's stock price traded 2.7% higher during pre-market hours on Tuesday, indicating a positive market response to the news and potentially boosting investor confidence.
- Future Outlook: With the resolution of compliance issues, Basel Medical is positioned to attract more investor interest in the future, enhancing its market position and competitiveness within the healthcare sector.
Basel Medical Group (BMGL) Receives Nasdaq Notice, Must Regain Compliance in 180 Days
- Nasdaq Warning: Basel Medical Group has received a notice from Nasdaq for failing to meet the $1 minimum bid price requirement after 30 consecutive trading days below this level, facing potential delisting risks and needing to take action within 180 days.
- Compliance Deadline: The company must maintain a closing bid price of at least $1 for 10 consecutive business days within 180 days, with a potential reverse stock split required before July 21, 2026, to meet Nasdaq's requirements.
- Response Plan: Basel Medical Group stated it is working with advisers to prepare a plan to address the listing non-compliance, aiming to implement effective measures to restore its stock price and ensure continued listing.
- Stock Price Reaction: Despite facing compliance challenges, Basel Medical Group's shares rose by 2.54%, indicating market confidence in the company's ability to regain compliance in the future.
Basel Medical Group Receives Delinquency Notice from Nasdaq
Delinquency Notification: Basel Medical Group Ltd. received a delinquency notification from Nasdaq due to an incomplete annual report for the fiscal year ending June 30, 2025, which lacked an auditor's opinion on its financial statements.
Compliance Timeline: The company has 60 days to submit a plan to regain compliance with Nasdaq rules, with a potential extension of up to 180 days if the plan is approved.
Financial Performance: For the fiscal year 2025, Basel Medical reported a net loss of S$12.09 million, a significant decline from a profit of S$2.07 million the previous year, despite an increase in sales from S$10.05 million to S$11.32 million.
Stock Performance: On the Nasdaq, BMGL shares closed at $1.14, reflecting a 2.52% decrease.
Basel Medical Group Faces Compliance Risk for Late 20-F Filing with Nasdaq
- Compliance Risk: Basel Medical Group has been notified by Nasdaq for failing to submit its 20-F annual report with an auditor's opinion, facing compliance risks that require a rectification plan within 60 days to avoid further penalties.
- Rectification Timeline: If the plan is accepted, Nasdaq may grant an exception of up to 180 days until May 18, 2026, to regain compliance, impacting the timeliness of future financial reports.
- Financial Audit Issues: The delay stems from the auditor NLA DFK Assurance PAC's failure to provide the necessary audit opinion, highlighting potential weaknesses in the company's financial transparency and compliance, which could affect investor confidence.
- Market Impact: Although trading on Nasdaq is currently unaffected, ongoing compliance issues may negatively impact the company's stock price and market reputation, necessitating stronger internal controls to prevent similar occurrences in the future.
Basel Medical Group Putting On Hold On The Acquisition of BTC Digital Asset
Acquisition on Hold: Basel Medical Group Ltd has decided to pause its acquisition of Bitcoin (BTC) digital assets due to ongoing regulatory reviews by US authorities, seeking greater clarity before proceeding with the transaction.
Company Overview: Basel Medical Group is a Singapore-based provider specializing in orthopedic and trauma services, with over 20 years of experience and a strong business model supported by relationships in various industries.
Basel Medical Group Puts the acquisition of BTC digital asset on hold
Acquisition on Hold: Basel Medical Group has decided to pause its acquisition of BTC digital assets, following a mutual agreement with Bitcoin holders.
Market Response: Following the announcement, BMGL shares experienced a 5% increase in post-market trading on Thursday.
